Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy
暂无分享,去创建一个
Iain Murray | Aida Hallam | Martha Stuffins | James Scuffham | Gerry Gillen | Jill Wevrett | Matthew Guy | Sofia Michopoulou | Andrew Fenwick | S. Michopoulou | J. Scuffham | A. Fenwick | G. Flux | M. Guy | I. Murray | Glenn Flux | Jill Tipping | R. Gregory | J. Wadsley | B. Murby | Jonathan Wadsley | Rebecca A Gregory | Jonathan Gear | Francesca Leek | Sarah J Chittenden | Brian Murby | Steve Jeans | Darren Morgan | David Hall | Heather Polydor | Colin Brown | Nathan Dickinson | Sarah Brown | J. Gear | G. Gillen | Francesca Leek | Jill Wevrett | J. Tipping | S. Chittenden | S. Jeans | S. Brown | D. Hall | Colin Brown | A. Hallam | M. Stuffins | Darren Morgan | Heather Polydor | Nathaniel Dickinson | Jill L Wevrett
[1] M. Kaminski,et al. Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity. , 2012, Cancer biotherapy & radiopharmaceuticals.
[2] Irène Buvat,et al. Multi-centre evaluation of accuracy and reproducibility of planar and SPECT image quantification: An IAEA phantom study. , 2017, Zeitschrift fur medizinische Physik.
[3] W. Waddington,et al. Objective comparison of lesion detectability in low and medium-energy collimator iodine-123 mIBG images using a channelized Hotelling observer , 2016, Physics in medicine and biology.
[4] Iain Murray,et al. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[5] A revised monitor source method for practical deadtime count loss compensation in clinical planar and SPECT studies. , 2015, Physics in medicine and biology.
[6] A. Chiti,et al. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[7] P. Green. Bayesian reconstructions from emission tomography data using a modified EM algorithm. , 1990, IEEE transactions on medical imaging.
[8] V S Hertzberg,et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. , 1983, The New England journal of medicine.
[9] E. Hoffman,et al. Quantitation in Positron Emission Computed Tomography: 1. Effect of Object Size , 1979, Journal of computer assisted tomography.
[10] J. I. Gear,et al. Development of patient-specific molecular imaging phantoms using a 3D printer. , 2014, Medical Physics (Lancaster).
[11] Glenn D. Flux,et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[12] Kris Thielemans,et al. Object dependency of resolution and convergence rate in OSEM with filtering , 2001, 2001 IEEE Nuclear Science Symposium Conference Record (Cat. No.01CH37310).
[13] W. Oyen,et al. Guidelines for radioiodine therapy of differentiated thyroid cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[14] V S Hertzberg,et al. Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] O. Schober,et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer , 2016 .
[16] F. Mottaghy,et al. Dose–Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT , 2016, The Journal of Nuclear Medicine.
[17] M S Rosenthal,et al. Quantitative SPECT imaging: a review and recommendations by the Focus Committee of the Society of Nuclear Medicine Computer and Instrumentation Council. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] J. Anthony Parker,et al. The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0* , 2012, The Journal of Nuclear Medicine.
[19] L. Moss,et al. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial , 2019, BMC Cancer.
[20] S. Larson,et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. , 2013, The New England journal of medicine.
[21] L. Moss,et al. SELIMETRY—a multicentre I-131 dosimetry trial: a clinical perspective , 2017, The British journal of radiology.
[22] S. Kappadath,et al. Characterization of the count rate performance of modern gamma cameras. , 2013, Medical physics.
[23] A. Sohlberg,et al. Fast Monte Carlo-simulator with full collimator and detector response modelling for SPECT , 2011, Annals of Nuclear Medicine.
[24] C A J van Gils,et al. Impact of reconstruction parameters on quantitative I-131 SPECT , 2016, Physics in medicine and biology.
[25] Michael Ljungberg,et al. MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications , 2013, The Journal of Nuclear Medicine.
[26] Antti Sohlberg,et al. Reduction of Collimator Correction Artefacts with Bayesian Reconstruction in Spect , 2010, International journal of molecular imaging.
[27] J A Sorenson. Deadtime characteristics of Anger cameras. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] D. McGowan,et al. Time to demand dosimetry for molecular radiotherapy? , 2015, The British journal of radiology.
[29] M. Dietlein,et al. Radioiodtherapie beim differenzierten Schilddrüsenkarzinom , 2016, Nuklearmedizin.
[30] Dale L. Bailey,et al. Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modality , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[31] T. Ohtake,et al. Estimation of deadtime in imaging human subjects , 1998, European Journal of Nuclear Medicine.